Nobivac Lepto

Authorised

- Leptospira interrogans, serogroup Canicola, serovar Portland-vere, strain Ca-12-000, Inactivated
- Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Copenhageni, strain Ic-02-001, Inactivated

Product identification

Medicine name:
Nobivac Lepto
Nobivac Lepto Vet. injektionsvæske, suspension

Active substance:
Leptospira interrogans, serogroup Canicola, serovar Portland-vere, strain Ca-12-000, Inactivated

Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Copenhageni, strain Ic-02-001, Inactivated

Target species:
Dog

Route of administration:
Subcutaneous use

Product details

Active substance and strength:
Leptospira interrogans, serogroup Canicola, serovar Portland-vere, strain Ca-12-000, Inactivated

990.00 unit(s) / 1.00 millilitre(s)

Leptospira interrogans, serogroup Icterohaemorrhagiae, serovar Copenhageni, strain Ic-02-001, Inactivated
699.00 unit(s) / 1.00 millilitre(s)

Pharmaceutical form:
Suspension for injection

Withdrawal period by route of administration:
Subcutaneous use:

- **Dog**

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI07AB01

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Denmark

Package description:
Plasic box containing 50 type I glass vials of 1 ml (1 dose) closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap
Plasic box containing 10 type I glass vials of 1 ml (1 dose) closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap
Cardboard box containing 50 type I glass vials of 1 ml (1 dose) closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap
Cardboard box containing 10 type I glass vials of 1 ml (1 dose) closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap

Additional information

Entitlement type:

Marketing Authorisation

Legal basis of product authorisation:
Legal basis not covered by Directive 2001/82/EC

Marketing authorisation holder:
Intervet International B.V.

Marketing authorisation date:
25/06/2003

Manufacturing sites for batch release:
INTERVET INTERNATIONAL B.V.

Responsible authority:
Danish Medicines Agency

Authorisation number:
34558

Date of authorisation status change:
25/06/2003

Reference member state:
Netherlands

Procedure number:
NL/V/0108/001

Concerned member states:
Belgium Denmark Greece Luxembourg Portugal Spain

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.
